Endpoints for Clinical Trials in Young Children with Cystic Fibrosis

The availability of sensitive, reproducible, and feasible outcome measures for quantifying lung disease in children with cystic fibrosis (CF) younger than 6 years is critical to the conduct of clinical trials in this important population. Historically, identifying and quantifying the presence of lun...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Davis, Stephanie D., Brody, Alan S., Emond, Mary J., Brumback, Lyndia C., Rosenfeld, Margaret
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Thoracic Society 2007
Soggetti:
Symposium: Measures for Development of New Therapies in Cystic Fibrosis
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2647606/
https://ncbi.nlm.nih.gov/pubmed/17652509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1513/pats.200703-041BR
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi